Advertisement
News
Advertisement

Biogen sees boost from new oral MS drug candidate

Mon, 04/11/2011 - 8:37am
Mass High Tech: The Journal of New England Technology

Biogen Idec (Nasdaq: BIIB) saw its stock rise more than 5 percent Monday morning, following the release of positive late-stage data for its experimental oral treatment for multiple sclerosis.

The Weston-based biotechnology company, which is known for its two blockbuster MS infusion treatments, Avonex and Tysabri, said that in the first of two Phase 3 clinical trials, its drug candidate met all of its endpoints in the study.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading